Pubblicazioni

Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy

2023 - LEUKEMIA RESEARCH

Maurillo, L.; Spagnoli, A.; Candoni, A.; Papayannidis, C.; Borlenghi, E.; Lazzarotto, D.; Fianchi, L.; SciumÃ¨, M.; Zannier, M. E.; Buccisano, F.; Del Principe, M. I.; Mancini, V.; Breccia, M.; Fanin, R.; Todisco, E.; Lunghi, M.; Palmieri, R.; Fracchiolla, N.; Musto, P.; Rossi, G.; Venditti, A.

Azacitidine to Consolidate and Deepen the Therapeutic Response Achieved by Intensive Induction Treatment in a Young Patient Affected by NPM1mut-AML Who Has Become Ineligible for High-Dose Consolidation

2022 - CHEMOTHERAPY

Cenfra, Natalia; Lapietra, Gianfranco; Perrone, Salvatore; Voso, Maria Teresa; Divona, Mariadomenica; Mecarocci, Sergio; La Barbera, Elettra Ortu; Cimino, Giuseppe

Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience

2020 - ANNALS OF HEMATOLOGY

Pepe, S.; Scalzulli, E.; Colafigli, G.; Di Prima, A.; Diverio, D.; Mancini, M.; Latagliata, R.; Martelli, M.; Foa, R.; Breccia, M.

Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience

2020 - ANNALS OF HEMATOLOGY

Pepe, Sara; Scalzulli, Emilia; Colafigli, Gioia; DI PRIMA, Alessio; Diverio, Daniela; Mancini, Marco; Latagliata, Roberto; Martelli, Maurizio; Robin, FoÃ ; Breccia, Massimo

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice

2019 - ANNALS OF HEMATOLOGY

Scalzulli, Emilia; Molica, Matteo; Alunni Fegatelli, Danilo; Colafigli, Gioia; Rizzo, Lorenzo; Mancini, Marco; Efficace, Fabio; Latagliata, Roberto; FoÃ , Robin; Breccia, Massimo

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice

2019 - ANNALS OF HEMATOLOGY

Scalzulli, Emilia; Molica, Matteo; ALUNNI FEGATELLI, Danilo; Colafigli, Gioia; Rizzo, Lorenzo; Mancini, Marco; Efficace, Fabio; Latagliata, Roberto; FoÃ &, Robin; Breccia, Massimo

Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia

2018 - ANNALS OF HEMATOLOGY

Maurillo, Luca; Buccisano, Francesco; Spagnoli, Alessandra; Voso, Maria Teresa; Fianchi, Luana; Papayannidis, Cristina; Gaidano, Gian Luca; Breccia, Massimo; Musto, Pellegrino; de Bellis, Eleonora; Del Principe, Maria Ilaria; Lunghi, Monia; Lessi, Federica; Martinelli, Giovanni; Venditti, Adriano

Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia

2016 - EUROPEAN JOURNAL OF HAEMATOLOGY

Voso, Maria Teresa; Niscola, Pasquale; Piciocchi, Alfonso; Fianchi, Luana; Maurillo, Luca; Musto, Pellegrino; Pagano, Livio; Mansueto, Giovanna; Criscuolo, Marianna; ALOE SPIRITI, Maria Antonietta; Buccisano, Francesco; Venditti, Adriano; Tendas, Andrea; Piccioni, Anna Lina; Zini, Gina; Latagliata, Roberto; Filardi, Nunzio; Fragasso, Alberto; Fenu, Susanna; Breccia, Massimo

Increased expression and activity of p75NTR are crucial events in azacitidine-induced cell death in prostate cancer

2016 - ONCOLOGY REPORTS

Gravina, Giovanni Luca; Marampon, Francesco; SanitÃ , Patrizia; Mancini, Andrea; Colapietro, Alessandro; Scarsella, Luca; Jitariuc, Ana; Biordi, Leda; Ficorella, Corrado; Festuccia, Claudio

Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN

2015 - LEUKEMIA RESEARCH

Andriani, Alessandro; Montanaro, Marco; Voso, Maria Teresa; VillivÃ , Nicoletta; Ciccone, Fabrizio; Andrizzi, Cristina; De Gregoris, Cinzia; Di Veroli, Ambra; Maurillo, Luca; Alimena, Giuliana; Latagliata, Roberto